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Abstract
Background: The primary objective of this study was to determine if elevated antiphospholipid
antibody titers were correlated with the presence of preeclampsia/eclampsia, systemic lupus
erythematosus (SLE), placental insufficiency, and a prolonged length of stay (PLOS), in women who
delivered throughout Florida, USA.
Methods:  Cross-sectional analyses were conducted using a statewide hospital database.
Prevalence odds ratios (OR) were calculated to quantify the association between elevated
antiphospholipid antibody titers and four outcomes in 141,286 women who delivered in Florida in
2001. The possibility that the relationship between elevated antiphospholipid antibody titers and
the outcomes of preeclampsia/eclampsia, placental insufficiency, and PLOS, may have been modified
by the presence of SLE was evaluated in a multiple logistic regression model by creating a composite
interaction term.
Results: Women with elevated antiphospholipid antibody titers (n = 88) were older, more likely
to be of white race and not on Medicaid than women who did not have elevated antiphospholipid
antibody titers. Women who had elevated antiphospholipid antibody titers had an increased
adjusted odds ratio for preeclampsia and eclampsia, (OR = 2.93 p = 0.0015), SLE (OR = 61.24 p <
0.0001), placental insufficiency (OR = 4.58 p = 0.0003), and PLOS (OR = 3.93 p < 0.0001). Patients
who had both an elevated antiphospholipid antibody titer and SLE were significantly more likely
than the comparison group (women without an elevated titer who did not have SLE) to have the
outcomes of preeclampsia, placental insufficiency and PLOS.
Conclusion:  This exploratory epidemiologic investigation found moderate to very strong
associations between elevated antiphospholipid antibody titers and four important outcomes in a
large sample of women.
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Background
The antiphospholipid syndrome (APS) is described as an
autoimmune disorder defined by both clinical and labo-
ratory criteria. Clinical criteria include vascular thrombo-
sis as well as unexplained fetal death, preeclampsia, and
eclampsia [1]. Laboratory criteria include the presence of
medium to high titers of lupus anticoagulant, anticardiol-
ipin, or anti-β2 glycoprotein-I antibodies [1]. APS is now
thought to be a systemic disease, affecting multiple organs
and systems [2]. Multiple medical and obstetric complica-
tions are commonly associated with APS such as preec-
lampsia, eclampsia, placental insufficiency,
thrombocytopenia, stroke, transient ischemic attack, pul-
monary embolism, livedo reticularis, Libman-Sacks endo-
carditis, multi-infarct dementia, migraine headache,
transverse myelitis, cutaneous ulcers, venous thrombosis,
and deep-vein thrombosis as well as other maladies [2-5].
Systemic lupus erythematosus (SLE) has historically been
strongly linked with APS. APS was first described as being
a subset of SLE [3]. Patients that have APS and SLE are
termed "secondary APS," while those that have APS with-
out clinical overt SLE or any symptom of SLE are termed
"primary APS" [4]. The prevalence of IgG anticardiolipin
antibodies in SLE patients has been shown to be as high
as 22.8%, while the prevalence of IgM and IgG anti-β2
glycoprotein-I antibodies in SLE patients has been shown
to be as high as 20% [4]. Many studies have examined
whether having APS with coexisting SLE causes a greater
increase in adverse outcomes such as pregnancy loss than
having APS alone [3]. Studies have shown that having SLE
and APS puts one at higher risk for thrombosis than hav-
ing either SLE or APS alone [3].
It is well known that APS and SLE increase maternal and
perinatal morbidity [6,7]. What is not known is the demo-
graphic and epidemiologic profile of patients with
increased antiphospholipid (AP) antibody titers, and the
prevalence of co-morbidities associated with the increased
titers. Also, certain populations may be at increased risk
for elevated AP antibody titers and might benefit from
more advanced diagnostic and therapeutic interventions.
We conducted an epidemiologic study to determine if ele-
vated antiphospholipid antibody titers (a criterion for
diagnosis of APS) are correlated with the presence of
preeclampsia and eclampsia, SLE, placental insufficiency,
and a prolonged length of stay (PLOS). The setting of the
analysis was a statewide hospital database. To our knowl-
edge this is the first investigation of its kind using inpa-
tient data from the Florida Agency for Health Care
Administration.
Methods
Source of patients/Inclusion criteria
Retrospective analyses were performed using a hospital
discharge dataset that was obtained from the Florida
Agency for Health Care Administration (Tallahassee, Flor-
ida). This public-use database includes discharge summa-
ries from all non-federal Florida hospitals except state
tuberculosis and state mental health hospitals. After data
are entered into this system, they are subjected to format-
ting and logic checks. The primary hospital submitting
patient information must then certify the data are correct
and verify the accuracy of a summary report before it is
released by the Agency for Health Care Administration.
This dataset contained clinical and demographic informa-
tion for 2,343,330 patients who were hospitalized for at
least one day and discharged in calendar year 2001. The
principal diagnosis and up to nine secondary diagnoses
were coded using the International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM). Up to
and including ten procedures (a principal procedure field
plus nine secondary procedures) could have been
recorded. Procedures were coded using the ICD-9-CM.
The current study focused on women who delivered dur-
ing their hospital stay. Women who had one of the fol-
lowing ICD-9-CM procedure codes in any of their ten
procedure fields were considered to have delivered a child
during that admission: 72, 72.1, 72.21, 72.29, 72.31,
72.39, 72.4, 72.51, 72.52, 72.53, 72.6, 72.71, 72.79, 72.8,
72.9, 72.9, 73.3, 73.59, 74, 74.1, 74.2, 74.4, 74.99.
Definitions of APS and outcomes
The ICD-9-CM code for antiphospholipid antibody syn-
drome is 795.79. The description of this code in the tabu-
lar list of ICD-9-CM is, "Other and unspecified
nonspecific immunological findings: Raised antibody
titer, Raised level of immunoglobulins."
Originally we aimed to study the following 14 outcomes
in addition to the aforementioned four outcomes; how-
ever, there were either too few cases overall (< 5) and/or
too few patients (< 5) who had both the exposure of ele-
vated antiphospholipid antibody titers and the outcome
of interest to conduct reliable multivariate regression
analyses: stroke, transient ischemic attack, pulmonary
embolism, arterial embolism and thrombosis, thrombo-
cytopenia, autoimmune hemolytic anemia, livedo reticu-
laris, Libman-Sacks endocarditis, multi-infarct dementia,
migraine headache, transverse myelitis, cutaneous ulcers,
venous thrombosis, and deep-vein thrombosis. Maternal
records are not linked to their respective infant records in
this database and therefore outcomes such as fetal death
could not be evaluated.BMC Pregnancy and Childbirth 2009, 9:11 http://www.biomedcentral.com/1471-2393/9/11
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If the patient's principal discharge diagnosis or any of the
nine secondary diagnosis fields contained code 795.79
then the patient was considered to have elevated
antiphospholipid antibody titers. Similarly, preeclampsia
and eclampsia were defined as ICD-9-CM code 642.40,
642.41, 642.42, 642.43, 642.44, 642.50, 642.51, 642.52,
642.53, 642.54, 642.60, 642.61, 642.62, 642.63, 642.64,
642.70, 642.71, 642.72, 642.73, or 642.74. Patients were
classified as having SLE if code 710.0 was found in any of
the ten diagnosis slots. The presence of codes 656.50,
656.51, and 656.53 in the electronic record identified
women with placental insufficiency. The 656.5 category is
also described as "poor fetal growth," "light-for-dates,"
and "small-for-dates" in the tabular ICD-9-CM list.
PLOS was defined as a length of stay (recorded in days)
that was greater than the 75th percentile in our sample. A
LOS of 3 days represented the 75th percentile in our study.
Dichotomizing LOS using the 75th percentile has been
used in previous clinical epidemiology analyses [8,9].
Data analysis
A cross-sectional study was conducted to determine if the
prevalence of the four outcomes stated above varied by
elevated antiphospholipid antibody titer status. Data were
analyzed using The SAS System for Windows 9.1.3 (The
SAS Institute, Inc., Cary, North Carolina). We performed
logistic regression using PROC LOGISTIC. Crude and
adjusted prevalence odds ratios (OR) were calculated for
preeclampsia/eclampsia, SLE, placental insufficiency, and
PLOS. An OR was considered statistically significant if the
95% confidence interval for the population OR excluded
the null value of one.
The following variables were evaluated for confounding
for each of the four outcomes: Age (in years), race-ethnic-
ity, and health insurance status. Race-ethnicity was origi-
nally an eight-level variable (7 racial ethnic groups plus a
category for missing). This variable was converted to a
four-level categorical variable: White Hispanic, Black non-
Hispanic, Other racial/ethnic group, and White non-His-
panic (referent). Asian and Pacific Islanders, Black His-
panics, American Indians/Eskimo/Aleut, and patients of
Other racial/ethnic groups were collapsed into a new
Other group. Our dichotomous health insurance variable
was created using the 14-level principal payer variable
found in the database: Patients whose primary insurer was
Medicaid or a Medicaid health maintenance organization
were compared to other patients. The "other" group
included various payers such as Medicare, charity, and
commercial insurance.
When preeclampsia/eclampsia was the outcome, the fol-
lowing variables were also considered potential con-
founders: Obesity or morbid obesity (defined as the
occurrence of ICD-9-CM codes 278.00 or 278.01 in any of
the ten discharge diagnosis fields), diabetes, and primi-
gravid status. Diabetes was defined as the presence of ICD-
9-CM code 250.0 to 250.9 (type I and II diabetes) or ICD-
9-CM code 648.8 (gestational diabetes) in any of the dis-
charge diagnosis fields. The database did not contain
detailed information on the patient's gravidity and parity;
however, several ICD-9-CM codes were used to attempt to
identify a primigravida, which was treated as a potential
confounder of the association between elevated antiphos-
pholipid antibody titers and preeclampsia. These codes
were 659.5 (elderly primigravida – a woman who will be
≥ 35 years of age at the expected date of delivery), 659.8
(young primigravida – a woman who will be < 16 years of
age at the expected date of delivery), V22.0 (supervision of
a normal first pregnancy), V23.81 (supervision of a high-
risk pregnancy, elderly primigravida), and V23.83 (super-
vision of a high-risk pregnancy, young primigravida). For
the outcome of PLOS, diabetes and gestational diabetes
(defined above) were considered potential confounders.
Backward elimination was utilized to identify confound-
ers for inclusion in the four final models. The significance
level for potential confounders to remain in the model
was 0.20. Mickey and Greenland have shown using Monte
Carlo simulations that this type of significance testing
method can perform acceptably in selecting confounders
if the significance level is set much higher than conven-
tional levels (for example, 0.20 or greater) [10]. The
method that we employed generally agrees with the
change-in-estimate method, which is popular among epi-
demiologists, as long as the alpha is 0.20 or higher [10].
(The change-in-estimate method does not rely on p-values
but rather the change in the OR associated with the expo-
sure of interest as one or more variables are added to the
model) [11].
In the final phase of the statistical analysis a composite
interaction variable was created to determine if there was
an interaction between elevated antiphospholipid anti-
body titers and SLE when the following variables were the
outcomes: preeclampsia/eclampsia, placental insuffi-
ciency, and PLOS [12]. To clarify, the following four risk
groups were formed to evaluate this potential interaction:
Had elevated AP antibody titers and SLE, had elevated AP
antibody titers but not SLE, no elevated AP antibody titers
but had SLE, and did not have elevated AP antibody titers
and did not have SLE. The last group served as the referent
or comparison group. The assessment of confounding was
identical to the procedure described above.
It is possible that several of our independent variables
were highly correlated (such as obesity and diabetes), a
phenomenon known as collinearity. Collinearity can
result in inaccurate estimates of regression coefficientsBMC Pregnancy and Childbirth 2009, 9:11 http://www.biomedcentral.com/1471-2393/9/11
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and p-values and can lead to reduced statistical power
[13,14]. Our analysis of the tolerances did not detect any
collinearity [15].
A total of 143,970 women who delivered during 2001 in
Florida were captured by this database. After deleting the
records of 2632 women who had missing values for race-
ethnicity, there were 141,338 records remaining. In an
attempt to only include one record per patient a small
number of women (n = 52) who were transferred to a
short-term general hospital or intermediate care facility
were deleted. This strategy was utilized because the dataset
lacked a unique patient identifier. The final sample size
was 141,286. Analysis of this dataset was approved by the
Institutional Review Board of the Texas Tech University
Health Sciences Center, El Paso, Texas.
Results
Selected demographic and clinical characteristics of the
sample are shown in Table 1. Women who carried the
diagnosis of elevated AP antibody titers comprised 0.06%
of the study sample (88/141,286). These women were
older and more likely to be of white race than women
who did not have elevated AP antibody titers (Table 1).
According to the principal payer code in the database, ele-
vated AP antibody titer patients were less likely to be Med-
icaid beneficiaries than patients free of elevated AP
antibody titers. The crude prevalence rates of all four out-
comes were higher in the elevated AP antibody titer group.
Approximately 0.8% and 0.2% of the entire sample had
an ICD-9-CM code indicating obesity and primigravida
status, respectively (data not shown).
Overall 6275 women carried the diagnosis of preeclamp-
sia/eclampsia (Table 1), and according to the ICD-9-CM
nomenclature, these women were classified into four
groups: 179 had eclampsia (2.85%), 610 had preeclamp-
sia or eclampsia superimposed on pre-existing hyperten-
sion (9.72%), 2052 had severe preeclampsia (32.70%),
and 3434 had mild or unspecified preeclampsia (54.73%)
(data not shown).
Crude (unadjusted) and adjusted prevalence ORs are
reported in Table 2. The ORs quantified the association
between elevated AP antibody titers and four outcomes:
preeclampsia or eclampsia, SLE, placental insufficiency,
and PLOS. Each of the four adjusted ORs was statistically
significant indicating that random chance was not a likely
explanation of the result. The adjusted OR for preeclamp-
sia/eclampsia revealed a moderate correlation with ele-
vated AP antibody titers while the ORs for placental
insufficiency and PLOS (both > 3.9) suggested strong rela-
tionships between elevated AP antibody titers and these
two outcomes. The strongest adjusted OR in Table 2 is for
the outcome of SLE: 61.24 (95% confidence interval:
24.29–154.44). The latter OR was adjusted for age and
race-ethnicity.
The adjusted ORs in Table 3 compare women in three risk
groups (elevated AP antibody titers and SLE, elevated AP
antibody titers and no SLE, no elevated AP antibody titers
and SLE) to women who are free of both conditions. The
results are read vertically for each outcome. Only five
women had both elevated AP antibody titers and SLE
noted in their discharge records (Table 3); however, hav-
ing both conditions was a strong correlate of the following
outcomes: preeclampsia/eclampsia, placental insuffi-
ciency, and PLOS.
Discussion
Large hospital datasets allow investigators to conduct
rapid exploratory studies that are population-based. Our
statewide cross-sectional study revealed moderate to very
strong associations between the risk factor of elevated AP
antibody titers and four important outcomes in a large
sample of women who delivered throughout Florida in
calendar year 2001 (n = 141,286). Women who had ele-
vated AP antibody titers had more than 60 times the odds
of having SLE than women who did not have elevated AP
antibody titers: Adjusted prevalence OR = 61.24 (p <
0.0001). This robust relationship is not unexpected. APS
and SLE are both autoimmune diseases and the former
was initially described as a subset of the latter [3]. While
both are characterized by inflammation, APS is typified
more by hypercoagulability and thrombotic events [3].
A strong correlation between elevated AP antibody titer
status and PLOS was also found (crude OR = 4.10). This
association persisted even after adjusting for age, race,
Medicaid status, and the presence of diabetes (adjusted
OR = 3.93). Length of stay is a recognized measure of dis-
ease severity when evaluating pregnancy-related morbid-
ity [16].
A relationship between APS and an increased risk of devel-
oping preeclampsia is known; however, whether or not
there is an association between high titers of AP antibod-
ies and preeclampsia in the absence of APS is unclear [5].
To clarify, women who satisfy both the clinical and labo-
ratory criteria for APS have a higher incidence of preec-
lampsia, but it is uncertain if merely a raised titer of AP
antibodies is linked to preeclampsia [5]. We report an
unadjusted prevalence of preeclampsia of 11.4% in
women with a raised antibody titer of AP antibodies and
a prevalence of preeclampsia of 4.4% in women who do
not have a raised titer (Table 1). Clark et al. recently sum-
marized the literature on the possible association between
high titers of circulating AP antibodies and preeclampsia
[5]. They report that the incidence of preeclampsia in
women with positive tests for AP antibodies ranges fromBMC Pregnancy and Childbirth 2009, 9:11 http://www.biomedcentral.com/1471-2393/9/11
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Table 1: Demographic and Clinical Characteristics of 141,286 Women who Delivered throughout Florida in 2001
Elevated Antiphospholipid Antibody Titers
Present
(n = 88)
Absent
(n = 141,198)
Variable Number (Percent) Number (Percent)
Age (years) *
11–19 2 (2.27) 16,155 (11.44)
20–29 33 (37.50) 72,316 (51.22)
30–39 47 (53.41) 48,751 (34.53)
40–49 6 (6.82) 3,964 (2.81)
≥ 50 0 (0.0) 12 (0.01)
Race-ethnicity
Black 12 (13.64) 32,940 (23.33)
White Hispanic 15 (17.05) 29,520 (20.91)
White Non-Hispanic 57 (64.77) 70,529 (49.95)
Other 4 (4.55) 8,209 (5.81)
Medicaid
Yes 16 (18.18) 58,333 (41.31)
No 72 (81.82) 82,865 (58.69)
Hospital mortality 0 (0.0) 21 (0.01)
Preeclampsia or eclampsia 10 (11.36) 6,265 (4.44)
Systemic lupus erythematosus 5 (5.68) 126 (0.09)
Placental insufficiency 6 (6.82) 2,347 (1.66)
Prolonged length of stay (> 3 days) 34 (38.64) 18,808 (13.32)
* Median age (range) of APS patients = 30.5 years (18 years-43 years) and median age of patients free of APS (range) = 27 years (11 years-54 years)BMC Pregnancy and Childbirth 2009, 9:11 http://www.biomedcentral.com/1471-2393/9/11
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11% to 50%. In contrast, the incidence of preeclampsia in
women who test negative was 2% to 4%.
A possible reason for the conflicting data arising from
studies of AP antibodies in preeclamptic women is differ-
ing thresholds for a positive test for AP antibodies and a
lack of standardization of the assays used in these investi-
gations [5]. According to Clark and colleagues, there is no
agreement regarding what tests are best suited for screen-
ing for APS in both the general and pregnant population
[5].
A strength of our investigation was the use of a large,
statewide database obtained from the Florida Agency for
Health Care Administration. The majority of civilian hos-
pitals in Florida are required to report their discharge data
to the Agency for Health Care Administration. To our
knowledge this is the first study of its kind to report on
Florida inpatients. This large data base includes 41,000
deliveries, so it is ideal for studying the epidemiology of
rare diseases/events that might take several years to collect
from prospective studies or case reports. Studies of hospi-
talized patients in which both the potential risk factor and
the outcome are diseases are prone to Berkson's bias [17].
Berkson was a physician at the Mayo Clinic who reported
the following phenomenon in 1946: Two diseases may
appear to be correlated with one another in a hospital-
based case-control study when in fact they are not simply
because individuals with two or more conditions are
more likely to be hospitalized than patients with one dis-
ease [17,18]. This selection bias may result in ORs that are
biased upwards.
A limitation of this and most other cross-sectional studies
is the doubt regarding whether or not temporality is
intact: Did the suspected risk factor truly occur before the
outcome or is it possible that the two are reversed? For
example, it is possible that a patient may have been diag-
nosed with SLE some time before the onset of elevated AP
antibody titers. A prospective study design would ensure
that reverse causality bias was not in effect.
Another limitation of the current study is the lack of data
on the accuracy of the ICD-9-CM coding in our database.
Lydon-Rochelle et al. studied the accuracy of the reporting
of particular maternal in-hospital diagnoses and intrapar-
tum procedures in the state of Washington, USA [19];
however, the sensitivity and specificity of the coding of the
conditions that we studied in this particular dataset are
unknown. We did not have access to medical records to
verify diagnoses. The prevalence of obesity and the pro-
portion of our sample that was classified as primigravidas
Table 2: Association between Elevated Antiphospholipid Antibody Titers (Present vs. Absent) and Four Adverse Outcomes in 141,286 
Women Delivering in Florida in 2001
Unadjusted Adjusted
Outcome Odds Ratio
[95% CI*]
P-value Odds Ratio
[95% CIa*]
P-value
Preeclampsia or Eclampsia 2.77
[1.44, 5.35]
0.002 2.93† 
[1.51, 5.69]
0.0015
Systemic lupus erythematosus 67.45
[26.90, 169.12]
< 0.0001 61.24‡
[24.29, 154.44]
< 0.0001
Placental insufficiency 4.33
[1.89, 9.93]
0.0005 4.58§
[2.00, 10.51]
0.0003
Prolonged length of stay¶ 4.10
[2.67, 6.30]
< 0.0001 3.93||
[2.55, 6.06]
< 0.0001
* CI: Confidence interval
† Adjusted for race, age, Medicaid status, diabetes, obesity, and primigravida status
‡ Adjusted for race and age
§ Adjusted for race, age, and Medicaid status
|| Adjusted for race, age, Medicaid status, and diabetes
¶ Defined as a length of stay of > 3 daysBMC Pregnancy and Childbirth 2009, 9:11 http://www.biomedcentral.com/1471-2393/9/11
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were much lower than expected. These codes may be
underutilized. In addition, there are no ICD-9-CM codes
identifying primigravidas between the ages of 16 and 34
years. In light of this situation residual confounding by
both of these factors may be present.
A further limitation is that we do not know which labora-
tory tests were done, the anticardiolipin, lupus anticoagu-
lant, the anti-B2 – GPI or another antiphospholipid test.
The lupus anticoagulant test is difficult to perform and
many times is not included. Additionally, we do not know
the titers for these positive tests. When women with low
titers are included, the outcome improves significantly.
Because of this, many studies have suggested that only
pregnant women with moderately or significantly ele-
vated titers should be included.
We did conduct sensitivity analyses of misclassification of
the exposure status (elevated antiphospholipid antibody
titer status) using standard formulae [20]. For three of our
four outcomes (preeclampsia, placental insufficiency, and
PLOS) the corrected ORs were similar to those found in
Table 2 (data not shown). For the outcome of SLE, the cor-
rected ORs ranged from 12.75 to 15.60, values that were
dramatically less than those found in Table 2 (ORs of
61.24 and 67.45). Nonetheless, the ORs for SLE corrected
for various degrees of misclassification still indicate the
presence of a very strong relationship.
Another drawback to this data base is that maternal and
neonatal data are not linked, so we do not have data on
IUGR or small for gestational age neonates. Also, this data
base does not include the details of treatment modalities
such as aspirin, heparin or corticosteroids and their effect
on fetal and neonatal outcomes.
Conclusion
Our epidemiologic study found that elevated AP antibody
titers were positively associated with the presence of four
major outcomes: preeclampsia/eclampsia, SLE, placental
insufficiency, and PLOS. Attentive clinical care is required
for best outcomes: surveillance to prevent placental insuf-
ficiency and to rule out intrauterine growth restriction and
frequent clinical follow up to decrease morbidity associ-
ated with preeclampsia and eclampsia and intrauterine
growth restriction. Antiphospholipid syndrome is one of
the few treatable causes of pregnancy loss, and successful
pregnancy rates of 70% or more can be achieved with
appropriate treatment [21,22].
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